Replies to post #687784 on NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Not true. Instead:

This is from the March 28, 2024 MHRA Newsletter.

Product approval announcements
We have continued work to publish announcements to coincide with the conclusion of regulatory assessments, delivering on a key objective as listed within our corporate plan to build public trust and understanding of our work.
These are issued simultaneously as outcomes are communicated to applicants, and we work in tandem with the company and across the health systems and health technology assessment bodies ahead of issuing press materials. Products we have recently communicated about include diagnostic tools for people with heart disease and prostate cancer; a treatment for ulcerative colitis that both NICE and the MHRA have simultaneously published their recommendations on, and a first anti-seizure medication to treat patients with rare epileptic seizure disorder.